EigenCloud founder: Team members used AI Agents to reproduce 80% of Google’s unpublished quantum achievements
Foresight News reports that EigenCloud founder Sreeram Kannan posted on Twitter that two students from his team managed to reproduce approximately 80% of Google’s undisclosed quantum breakthrough results over the weekend using an AI Agent. One undergraduate, Gautham Anant, made about a twofold improvement to existing quantum cryptography circuits, while another 18-year-old researcher, Gajesh, used a customized Agent cluster to further enhance the results, reaching approximately 80% of Google’s undisclosed results. This work targets elliptic curve point addition circuits, which are a core operation for Shor’s algorithm to break ECDSA (the signature scheme used by Bitcoin and other assets). At the same time, Sreeram Kannan announced the launch of the first open challenge, the Quantum ECC Addition Challenge, encouraging more people and their Agents to participate in optimization. In the future, further open challenges in mathematics are planned in collaboration with Dan Boneh from Stanford University, Justin Drake from the Ethereum Foundation, and others.
Previously, the Google Quantum AI team had demonstrated that elliptic curve cryptography could be broken with significantly fewer resources than previously expected and validated their results through zero-knowledge proof, but did not disclose the specific algorithm.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
